Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Time is of the essence: the impact of precision oncology in Australia
A new landmark report by Omico confirms precision oncology – the use of genomics to…
Growing use of GLP-1 receptor agonists for obesity among patients with cancer raises need for evidence-based guidance
A new research letter published in JAMA Oncology reports that semaglutide and tirzepatide—two widely used…
Breakthrough in cancer immunotherapy using marine bacteria
A research team led by Professor Eijiro Miyako at the Graduate School of Advanced Science…
Screening for fear of cancer recurrence: Podcast with Dr Ben Smith
How can we distinguish between fear of cancer recurrence and generalised anxiety? How can we measure fear of recurrence and…
Advancements in managing EGFR-mutant and ALK-positive non–small cell lung cancer with brain metastases
- Non small cell lung cancer with SMARCA4 deficiency harbouring rare EGFR mutations exhibited significant tumour response when treated with afatinib
- Preventive healthcare utilisation among adults eligible for lung cancer screening
- Breakthrough combination therapy tackles drug resistance in lung cancer with common KRAS mutation
Inherited genes play a larger role in melanoma risk than previously believed
- ASCO 2024: Dual immunotherapy treatment before surgery, rather than after, improves outcomes in melanoma patients
- ASCO 2024: Promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumours, especially in melanoma
- New biomarkers of response in melanoma immunotherapy
Brain tumours are cognitive parasites – how brain cancer hijacks neural circuits and causes cognitive decline
Saritha Krishna, University of California, San Francisco and Shawn Hervey-Jumper, University of California, San Francisco Researchers have long known that…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.